Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical Trials
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2011/08/10
-
Indian UGC (journal)
-
Refrences20
-
Citations43
-
H. Amy Xia a Amgen, Inc. , Thousand Oaks, California, USA
-
Haijun Ma a Amgen, Inc. , Thousand Oaks, California, USA
-
Bradley P. Carlin b University of Minnesota , Twin Cities, Minnesota, USA
Cite
Amy Xia, H., et al. “Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical Trials”. Journal of Biopharmaceutical Statistics, vol. 21, no. 5, 2011, pp. 1006-29, https://doi.org/10.1080/10543406.2010.520181.
Amy Xia, H., Ma, H., & Carlin, B. P. (2011). Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical Trials. Journal of Biopharmaceutical Statistics, 21(5), 1006-1029. https://doi.org/10.1080/10543406.2010.520181
Amy Xia, H., Haijun Ma, and Bradley P. Carlin. “Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical Trials”. Journal of Biopharmaceutical Statistics 21, no. 5 (2011): 1006-29. https://doi.org/10.1080/10543406.2010.520181.
Amy Xia H, Ma H, Carlin BP. Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical Trials. Journal of Biopharmaceutical Statistics. 2011;21(5):1006-29.
Journal Categories
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
Science
Mathematics
Probabilities
Mathematical statistics
You May Also Like
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studies
- Sample size of 12 per group rule of thumb for a pilot study
- Guidelines for accurate EC50/IC50 estimation
- Quantifying heterogeneity in a meta‐analysis
- Multiple imputation using chained equations: Issues and guidance for practice
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team | Clinical Trials |
| 74 | 2009 |
Use of the false discovery rate for evaluating clinical safety data | Statistical Methods in Medical Research |
| 84 | 2004 |
| 10.1201/b14884 | 2008 | |||
| 10.1201/b14884 | 2002 | |||
| 10.1201/b14884 | 2007 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Tree‐temporal scan statistics for safety signal detection in vaccine clinical trials | Pharmaceutical Statistics |
| 2024 | |
Bayesian generalized linear low rank regression models for the detection of vaccine‐adverse event associations | Statistics in Medicine |
| 2023 | |
| Assessing the incidence and severity of drug adverse events: a Bayesian hierarchical cumulative logit model | Journal of Biopharmaceutical Statistics |
| 2023 | |
| BAHAMA: A Bayesian Hierarchical Model for the Detection of MedDRA®-Coded Adverse Events in Randomized Controlled Trials | Drug Safety |
| 1 | 2022 |
| Zero-Inflated Binomial Model for Meta-Analysis and Safety-Signal Detection | Therapeutic Innovation & Regulatory Science |
| 2 | 2022 |
Citations Analysis
The category
Science: Mathematics: Probabilities. Mathematical statistics 26
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Meta-analysis of clinical trial safety data in a drug development program: Answers to frequently asked questions and was published in 2012. The most recent citation comes from a 2024 study titled Tree‐temporal scan statistics for safety signal detection in vaccine clinical trials. This article reached its peak citation in 2020, with 8 citations. It has been cited in 15 different journals, 20% of which are open access. Among related journals, the Pharmaceutical Statistics cited this research the most, with 6 citations. The chart below illustrates the annual citation trends for this article.